Revatio® (sildenafil) – Expanded indication
January 31, 2023 - The FDA approved Viatris’ Revatio (sildenafil), in pediatric patients 1 to 17 years old, for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underly improvements in exercise.
Top